EU MDR Article 61: Clinical Evaluation, Clinical Data and PMCF Requirements

1. Key takeaways

Under Article 61 of the MDR, manufacturers must demonstrate conformity of their devices with the relevant general safety and performance requirements of Annex I through clinical evaluation. The clinical evaluation must be based on sufficient clinical data and follow the plan and procedures laid down in Part A of Annex XIV. Where clinical data are insufficient, a clinical investigation must be carried out under Articles 62 to 80. After the device is on the market, post-market clinical follow-up (PMCF) must continue under Part B of Annex XIV.

These provisions operate as one continuous system rather than as separate pre-market and post-market tasks. The sufficiency of the clinical data is judged against the claims, the intended purpose and the risk profile of the device; a gap in the data either narrows the claims or forces a clinical investigation. Once the device is on the market, the PMCF activities feed new experience back into the clinical evaluation, which must be updated in step. A project that treats the clinical evaluation as a one-off pre-market document will find that the same deficiencies reappear in two places at once: in the notified body review before certification, and in the post-market surveillance findings afterwards, each time at a higher cost than if the system had been built as a loop from the beginning.

2. Legal basis

The core obligations come from Regulation (EU) 2017/745, adopted on 2017-04-05 and applicable since 2021-05-26, including the definitions of clinical data in Article 2(48) and of clinical evaluation in Article 2(51). The harmonisation procedure for clinical investigations in Article 78(14) was amended by Regulation (EU) 2024/1860, adopted on 2024-06-13 and in force from 2024-07-09, which introduced a phased application tied to the publication of an EUDAMED-related notification, as explained below.

3. Expert insights

Insight one: clinical evaluation is a process, not a report.

The clinical evaluation consists of planning, identification of data, appraisal of data, analysis of data and the conclusion, and it produces the clinical evaluation report (CER), which enters the technical documentation and feeds the update cycles of the quality management system. Treating it as a document written once before market placement causes failures in two places simultaneously: in the notified body review, where the report must demonstrate a living process, and in post-market surveillance, where the report must absorb incoming PMCF data. The report is the visible output, but the reviewers assess the process behind it, including how the plan was set, how the literature search was conducted and how the conclusions track the evidence actually gathered.

Insight two: the three sources of clinical data carry different evidentiary thresholds.

Clinical data may come from clinical investigations of the device itself, from data on equivalent devices, and from the literature and post-market experience. When data from an equivalent device are used, equivalence must be demonstrated across three dimensions, technical, biological and clinical, which is a markedly stricter standard than under the former directives. Under the old regime, a general assertion of similarity was often sufficient to justify using another manufacturer’s data; under the MDR, each dimension must be argued on its own terms with supporting evidence, and access to the equivalent device’s data must be lawful. Projects that plan around equivalence claims must therefore secure data access early, since this is where most equivalence-based evaluations stall.

Insight three: the harmonisation procedure in Article 78(14) was changed in 2024 to a phased application.

Under Article 78(14) as amended by Regulation (EU) 2024/1860: five years after the publication of the notification referred to in Article 34(3), concerning the functionality of the electronic system under Article 33(2)(e), all Member States must apply the harmonisation procedure provided for in that article; before that date, and from six months after the publication of that notification, the procedure applies only in those Member States that have agreed to apply it, in the countries where the clinical investigations take place. This change is directly linked to the activation of the EUDAMED clinical investigation module. Sponsors of multi-country investigations must track which phase applies at the time of their submission, because the applicable coordination rules differ between the two periods.

Insight four: clinical investigations are linked to vigilance obligations.

Under Article 80, serious adverse events and device deficiencies occurring during clinical investigations must be reported in accordance with the MDR. The Commission explanatory material states expressly that reporting of serious adverse events and device deficiencies observed during clinical investigations must follow the MDR. The same requirement applies to legacy devices, under Article 120(3d). Sponsors should therefore integrate investigation reporting into the company vigilance procedures from the start, rather than operating a separate lightweight channel for the study period, which historically produced inconsistent reporting and missed timelines.

4. Practical recommendations

1. Start with an inventory of the clinical data: whether the existing data can support the relevant requirements of Annex I, and where the gaps are, before deciding whether an investigation is needed.
2. Structure the clinical evaluation report according to Part A of Annex XIV and give an explicit benefit-risk conclusion, so that the reasoning from data to conclusion is visible to the reviewer.
3. When relying on an equivalent device, argue equivalence item by item across the technical, biological and clinical dimensions, and avoid blanket equivalence statements without dimensional analysis.
4. For multi-centre clinical investigations, confirm in advance the application status of the Article 78 harmonisation procedure and the position of the Member States where the investigation sites are located.
5. Establish a periodic update mechanism for the clinical evaluation, linked to PMCF data and vigilance signals, so that the report stays current without emergency rewrites.

5. Verification checklist

• □ The clinical data inventory has been completed and a gap list produced
• □ The clinical evaluation report complies with the structure of Part A of Annex XIV
• □ Equivalence has been argued across the technical, biological and clinical dimensions
• □ The application status of the Article 78 harmonisation procedure in the target Member States has been confirmed
• □ A periodic update mechanism for the clinical evaluation has been established
• □ The PMCF plan has been linked to the clinical evaluation

GRZAN supports manufacturers, authorised representatives and importers across the EU MDR market with CE marking pathway selection and classification strategy, including clinical data inventory, clinical evaluation reporting to the Annex XIV standard, equivalence demonstrations and PMCF design. For a practical estimate of evidence timelines and documentation effort for your portfolio, contact GRZAN at info@grzanglobal.com.

Regulatory information verified as of 2026-10-29.